clinical trial · NCT02912260
Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)
Non-alcoholic SteatohepatitisMGL-3196Placebo
brief summary
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in participants with biopsy-proven Non-alcoholic Steatohepatitis (NASH).
started
Oct 18, 2016
primary completion
Oct 25, 2017
completion
Nov 23, 2021
last updated
Dec 23, 2025
official title
A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol